Study of CAD-1883 for Spinocerebellar Ataxia

Stopped In January 2021 Novartis acquired Cadent Therapeutics. As part of a pipeline reassessment, the Synchrony-1 trial will not proceed as initially scheduled.

Conditions

• Spinocerebellar Ataxias
• Spinocerebellar Ataxia Type 1
• Spinocerebellar Ataxia Type 2
• Spinocerebellar Ataxia Type 3
• Spinocerebellar Ataxia Type 6
• Spinocerebellar Ataxia Type 7
• Spinocerebellar Ataxia Type 8
• Spinocerebellar Ataxia Type 10
• Spinocerebellar Ataxia Type 17
• ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1

Interventions

• DRUG: CAD-1883
• DRUG: Placebos

Sponsor

Cadent Therapeutics